Evidence map›Paper›PMID 23129620›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2012

Turning self-destructing Salmonella into a universal DNA vaccine delivery platform.

Wei Kong, Matthew Brovold, Brian A Koeneman, Josephine Clark-Curtiss, Roy Curtiss

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 90 citations in OpenAlex.

  1. Developing Antiviral Vaccines Based on AttenuatedPathogens (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Protection AgainstVaccines · 2026
    Article
  9. Article
  10. An OralPathogens (Basel, Switzerland) · 2025
    Article
  11. Article
  12. Vaccines · 2025
    Review
  13. Oral Vaccination with AttenuatedPathogens (Basel, Switzerland) · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. Biomolecules · 2024
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Wei KongCenter for Infectious Diseases and Vaccinology at the Biodesign Institute, and School of Life Sciences, Arizona State University, Tempe, AZ 85287-5401, USA.
Matthew Brovold
Brian A Koeneman
Josephine Clark-Curtiss
Roy Curtiss
Arizona State University · US

Funding

Recombinant Attenuated Salmonella Vaccines for HumansR01AI056289 · NIAID · WASHINGTON UNIVERSITY · PI CLARK-CURTISS, JOSEPHINE E, CURTISS III, ROY · 2003 to 2018
$5.8M
Recombinant Attenuated Bacterial Vaccines Against Biodefense AgentsR01AI093348 · NIAID · UNIVERSITY OF FLORIDA · PI CURTISS III, ROY · 2011 to 2015
$5.0M
Salmonella anti-influenza DNA &antigen delivery vaccineR01AI065779 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI CURTISS III, ROY · 2005 to 2008
$2.2M
Engineered self-destructing Salmonella as a colorectal cancer cureR21CA152456 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI KONG, WEI · 2010 to 2011
$359k
NCI NIH HHS R21 CA152456NCI NIH HHS R21CA152456NIAID NIH HHS R01 AI056289NIAID NIH HHS R01 AI065779NIAID NIH HHS R01 AI093348
6 · The paper itself

Abstract

We previously developed a biological containment system using recombinant Salmonella Typhimurium strains that are attenuated yet capable of synthesizing protective antigens. The regulated delayed attenuation and programmed self-destructing features designed into these S. Typhimurium strains enable them to efficiently colonize host tissues and allow release of the bacterial cell contents after lysis. To turn such a recombinant attenuated Salmonella vaccine (RASV) strain into a universal DNA vaccine-delivery vehicle, our approach was to genetically modify RASV strains to display a hyperinvasive phenotype to maximize Salmonella host entry and host cell internalization, to enable Salmonella endosomal escape to release a DNA vaccine into the cytosol, and to decrease Salmonella-induced pyroptosis/apoptosis that allows the DNA vaccine time to traffic to the nucleus for efficient synthesis of encoded protective antigens. A DNA vaccine vector that encodes a domain that contributes to the arabinose-regulated lysis phenotype but has a eukaryotic promoter was constructed. The vector was then improved by insertion of multiple DNA nuclear-targeting sequences for efficient nuclear trafficking and gene expression, and by increasing nuclease resistance to protect the plasmid from host degradation. A DNA vaccine encoding influenza WSN virus HA antigen delivered by the RASV strain with the best genetic attributes induced complete protection to mice against a lethal influenza virus challenge. Adoption of these technological improvements will revolutionize means for effective delivery of DNA vaccines to stimulate mucosal, systemic, and cellular protective immunities, and lead to a paradigm shift in cost-effective control and prevention of a diversity of diseases.

Indexed as

Gene Transfer TechniquesActive Transport, Cell NucleusAnimalsAntibodies, BacterialAntibody FormationApoptosisBase SequenceDeoxyribonucleasesGenes, BacterialGenetic EngineeringGenetic VectorsHemagglutinin Glycoproteins, Influenza VirusImmunizationMiceMolecular Sequence DataPlasmidsAntibodies, BacterialDeoxyribonucleasesHemagglutinin Glycoproteins, Influenza VirusSalmonella VaccinesVaccines, AttenuatedVaccines, DNAVaccines, Synthetic

Identifiers

PMID23129620
PMCPMC3511069
OpenAlexW2000888298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.